Anna Maria Lombardi

Novel point mutation in a leucine-rich repeat of the GPIbα chain of the platelet von Willebrand factor receptor, GPIb/IX/V, resulting in an inherited dominant form of Bernard-Soulier syndrome affecting two unrelated families: the N41H variant

This reports describes a new variant of heterozygous Bernard-Soulier syndrome with autosomal dominant inheritance. In Italy, a significant proportion of patients with autosomal dominant inheritance of macrothrombocytopenia have been recognized as having heterozygous Bernard-Soulier syndrome carrying the Bolzano-type defect. This condition prompted a systematic review of our out-patients with chronic isolated macrothrombocytopenia. We recognized that the affected members of two unrelated families represented a new variant of heterozygous Bernard-Soulier Syndrome with autosomal dominant inheritance. Sequencing analysis of the GPIbα gene revealed a novel heterozygous mutation, A169C, resulting in an N41H substitution in the protein. This aminoacid belongs to the first leucine-rich repeat of the chain. The molecular modeling suggests that the replacement of the N41 with a histidine (N41H) drastically disturbs the structure of the first portion of GPIbα N-terminal, directly involved in von Willebrand factor binding. As a consequence, platelet aggregation to 1.2 mg/mL of ristocetin is slightly impaired and flow cytometry reveals a reduced binding of monoclonals directed against N-terminal epitopes of the GPIbα.

Early predictors of transplant-related mortality (TRM) after allogeneic bone marrow transplants (BMT): blood urea nitrogen (BUN) and bilirubin

Transplant-related mortality (TRM) following allo- geneic bone marrow transplantation (BMT) remains a major concern and early identification of patients at risk may be clinically relevant. In this study we describe a predictive score based on bilirubin and blood urea nitrogen (BUN) levels on day +7 after BMT. The patient population consisted of 309 consecutive patients who underwent BMT from sibling (n = 263) or unrelated donors (n = 46) for hematologic disorders between December 1990 and December 1996. Of 27 laboratory tests taken on day +7 after BMT, serum bilirubin (P = 0.02) and BUN (P = 0.007) were found to be independent predictors of TRM in multivariate analysis. The median levels of bilirubin (0.9 mg/dl) and of BUN (21 mg/dl) were then used as a cut-off and a score of 1 was given for values equal/greater than the median. There were 216 patients with scores 0–1 (low risk) on day +7 (bilirubin <0.9 and/or bun <21) and 93 patients with score 2 (high risk) (bilirubin ⩾0.9 and bun ⩾21): the latter had more grade iii–iv acute graft-versus-host disease (P = 0.03), slower neutrophil (P = 0.02) and slower platelet engraftment (P = 0.002). The actuarial 5 year TRM is 22% for low risk vs44% for high risk patients (P = 0.0003). For HLA-identical siblings TRM is 20% vs35% (P = 0.01), for unrelated donors it is 20% vs 65% (P = 0.01). Day +7 score was highly predictive of TRM on multivariate analysis (hazard ratio 1.9, P < 0.01), after adjustment for year of transplant (P < 0.00001), unrelated vs sibling donors (P = 0.001), patient age (P = 0.01) and diagnosis (P = 0.01). These results were validated on an independent group of 82 allogeneic BMT recipients in a pediatric Unit who showed an actuarial TRM of 16% for low risk vs 46% for high risk patients (P = 0.002). This study suggests that it may be possible to identify patients with different risks of TRM on day +7 after BMT: high risk patients could be eligible for programs designed to intensify prophylaxis of post-transplant complications.

Presence of anti-ADAMTS13 antibodies in obesity

Eur J Clin Invest 2012; 42 (11): 1197–1204

Occurrence of thrombosis in congenital thrombocytopenic disorders: a critical annotation of the literature.

Patients with a low platelet count are prone to bleeding. The occurrence of a thrombotic event in congenital thrombocytopenic patients is rare and puzzling. At least nine patients with Glanzmann thrombasthenia have been reported to have had a thrombotic event, eight venous and one arterial (intracardiac, in the left ventricle). On the contrary, three patients with Bernard–Soulier syndrome have been shown to have had arterial thrombosis (myocardial infarction) but no venous thrombosis. Finally, seven patients with the familiar macrothrombocytopenia due to alterations of the MYH9 gene have been reported to have had thrombosis (five myocardial infractions, one ischemic stroke, one deep vein thrombosis and one portal vein thrombosis). The significance of these findings is discussed with particular emphasis on the discrepancy between venous and arterial thrombosis seen in patients with Glanzmann thrombasthenia and Bernard–Soulier syndrome.

Allogeneic hemopoietic stem cell transplants for patients with relapsed acute leukemia: long-term outcome

We assessed the long-term outcome of patients with relapsed acute myeloid (n=86) or acute lymphoid leukemia (n=66), undergoing an allogeneic hemopoietic stem cell transplantation in our unit. The median blast count in the marrow was 30%. Conditioning regimen included total body irradiation (TBI) (10–12 Gy) in 115 patients. The donor was a matched donor (n=132) or a family mismatched donor (n=20). Twenty-two patients (15%) survive disease free, with a median follow-up of 14 years: 18 are off medications. The cumulative incidence of transplant related mortality is 40% and the cumulative incidence of relapse related death (RRD) is 45%. In multivariate analysis of survival, favorable predictors were chronic graft-versus-host disease (GvHD) (P=0.0003), donor other than family mismatched (P=0.02), donor age less than 34 years (P=0.02) and blast count less than 30% (P=0.07). Patients with all four favorable predictors had a 54% survival. In multivariate analysis of relapse, protective variables were the use of TBI (P=0.005) and cGvHD (P=0.01). This study confirms that a fraction of relapsed leukemias is cured with an allogeneic transplant: selection of patients with a blast count <30%, identification of young, human leukocyte antigen-matched donors and the use of total body radiation may significantly improve the outcome.

Serum cholinesterase is an early and sensitive marker of graft-versus host-disease (GVHD) and transplant-related mortality (TRM)

Serum cholinesterase (CHE) has been reported to be a significant indicator of liver function and prognosis in patients with cirrhosis. On the other hand, liver complications are frequent following allogeneic stem cell transplantation (HSCT). We therefore tested whether CHE was predictive of graft-versus-host disease and outcome in HSCT recipients. We studied 689 patients receiving a HSCT from an HLA-identical sibling (SIB) (n = 511), an alternative donor (n = 173) or a syngeneic twin (n = 5). Acute graft-versus-host disease (GVHD) was scored as 0–I, II, III–IV in 325 (47%), 279 (41%), and 85 patients (12%) respectively; 190 (28%) patients died of transplant-related complications (TRM). On day −7 the median CHE serum level was comparable in patients who either survived or died of TRM (5900 IU/l). On day 0, serum CHE levels were respectively 2310 and 2120 IU/l (P = NS) indicating the impact of the conditioning regimen. On day +7 after HSCT, the median level for surviving patients was 2598 IU/l vs 2309 IU/l for patients who subsequently died (P = 0.0002), on day +21 CHE levels were respectively 3348 vs 2528 IU/l (P < 0.00001), on day +50, 3575 vs 2358 IU/l (P < 0.00001) and on day +100 4193 vs 2729 IU/l (P < 0.00001). CHE levels on day +50 strongly correlated with aGVHD (3803 vs 3070 vs 1933 IU/l for patients with GVHD grade 0–I, II, and III–IV, respectively (P < 0.00001) and relapse (3569 for patients relapsing vs 3115 IU/l for patients not relapsing, P = 0.0006). In conclusion, (1) serum cholinesterase is a simple and reliable marker of acute GVHD and transplant-related complications; and (2) high CHE levels on day +50 predict relapse. If confirmed, the latter patients may be elegible for early reduction of immunosuppressive therapy.Bone Marrow Transplantation (2001) 28, 1041–1045.

Familial acquired thrombotic thrombocytopenic purpura: immunogenetic link with HLA-DRB1*11 and DQB1*03 antigens

A.T., Huhn, M., Fischer, R., Thepen, T. & Barth, S. (2013) Microtubule-associated protein tau facilitates the targeted killing of proliferating cancer cells in vitro and in a xenograft mouse tumour model in vivo. British Journal of Cancer, 109, 1570–1578. Hu, X., Wei, H., Xiang, L., Chertov, O., Wayne, A.S., Bera, T.K. & Pastan, I. (2013) Methylation of the DPH1 promoter causes immunotoxin resistance in acute lymphoblastic leukemia cell line KOPN-8. Leukemia Research, 37, 1551–1556. Mathew, M. & Verma, R.S. (2009) Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy. Cancer Science, 100, 1359–1365. Mladenov, R., Hristodorov, D., Cremer, C., Hein, L., Kreutzer, F., Stroisch, T., Niesen, J., Brehm, H., Blume, T., Brummendorf, T.H., Jost, E., Thepen, T., Fischer, R., Stockmeyer, B., Barth, S. & Stein, C. (2015) The Fc-alpha receptor is a new target antigen for immunotherapy of myeloid leukemia. International Journal of Cancer, 137, 2729– 2738. Saxena, S.K., Rybak, S.M., Davey, R.T. Jr, Youle, R.J. & Ackerman, E.J. (1992) Angiogenin is a cytotoxic, tRNA-specific ribonuclease in the RNase A superfamily. The Journal of Biological Chemistry, 267, 21982–21986. Valerius, T., Stockmeyer, B., van Spriel, A.B., Graziano, R.F., van den Herik-Oudijk, I.E., Repp, R., Deo, Y.M., Lund, J., Kalden, J.R., Gramatzki, M. & van de Winkel, J.G. (1997) FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy. Blood, 90, 4485–4492. Wei, H., Xiang, L., Wayne, A.S., Chertov, O., FitzGerald, D.J., Bera, T.K. & Pastan, I. (2012) Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy. Proceedings of the National Academy of Sciences of the United States of America, 109, 6898–6903. Weidle, U.H., Tiefenthaler, G., Schiller, C., Weiss, E.H., Georges, G. & Brinkmann, U. (2014) Prospects of bacterial and plant protein-based immunotoxins for treatment of cancer. Cancer Genomics & Proteomics, 11, 25–38.

Bleeding manifestations in heterozygotes with prothrombin deficiency or abnormalities vs. unaffected family members as observed during a long follow-up study

&NA; To investigate the prevalence of bleeding in heterozygotes for prothrombin deficiencies. Homozygotes or compound heterozygotes with Factor II (FII) levels of less than 10% of normal are always severely symptomatic. On the contrary little is known about the heterozygous population who have FII levels around 40–50% of normal. Forty-four patients heterozygous for this defect, in comparison with age and sex matched 44 unaffected family members, have been followed during a mean observational period of 22.5 years (range 4–35 years). The study was carried out in Padua between the years 1971 and 2010. The mean prothrombin activity was 0.49 IU/dl (range 0.38–0.62) and 0.91 IU/dl (range 0.81–1.10) in the heterozygotes and in the normal counterparts, respectively. In total, 14 patients showed bleeding manifestations vs. only three among the controls. Bleeding was sometimes spontaneous but more frequently occurred after tooth extractions, surgery, or delivery. Some heterozygous patients had also to be given replacement therapy to control the bleeding. No substitution therapy was ever needed for the normal counterparts. The prothrombin activity levels in the patients who were symptomatic tended to be lower than in those who remained asymptomatic. The difference in the frequency of bleeding and in the bleeding score between patients and unaffected family members was statistically significant (P = 0.007 and 0.0007). Prothrombin levels of about 40–50% of normal may not represent well tolerated hemostatic levels in case of surgical procedures, tooth extraction, or delivery. These data may have general clinical significance even for patients who have acquired defects.

Factor X Friuli Coagulation Disorder: Almost 50 Years Later

The story of factor X (FX) Friuli. Factor X Friuli was discovered in 1969 to 1970. However, the story of that disease was an international event since patients with this defect were studied in France and in Italy, and different diagnoses were reached—FVII; FX; combined prothrombin complex; and combined FII, FVII, and FX deficiencies. The diagnostic difficulties were due to the peculiar clotting pattern presented by these patients, namely, prolonged partial thromboplastin time, prolonged prothrombin time but normal Russell viper venom clotting time. Only suitable anti-FX antisera clarified the pattern. Altogether 12 homozygotes and 102 heterozygotes have been followed during 4 decades. Six homozygotes died, 2 of them due to HIV infection and 1 due to hepatitis B liver cirrhosis. The other 3 died of nontransfusion-related morbidity. Bleeding tendency has been moderate in agreement with the extrinsic or intrinsic system assay results—FX level of 4% to 5% is considered normal. Heterozygotes may present occasional bleeding manifestations usually during surgery or delivery. Molecular analysis have shown that the mutation responsible for the defect is a Pro343Ser substitution in exon 8. Chimeric FX Friuli mice have been useful in studying the effect of FX levels on embryonic or natal mortality of these animals. No new homozygote but several heterozygotes have been recently seen. The study of FX Friuli has revolutionized the diagnostic approach to FX deficiencies. The FX should be assayed by all assay systems. The FX Friuli has never been described in any other country, and all patients studied come from the Friuli Meduna River Valley.

New heterozygous variant in GP1BB gene is responsible for an inherited form of macrothrombocytopenia

Ezio Zanon Samantha Pasca Cristina Santoro Gabriella Gamba Sergio M. Siragusa Angiola Rocino Isabella Cantori Augusto B. Federici Luciana Mameli Gaetano Giuffrida Anna Falanga Corrado Lodigiani Rita C. Santoro Marta Milan Chiara Ambaglio Mariasanta Napolitano Maria G. Mazzucconi Haemophilia Centre, University Hospital of Padua, Padova, Italy, Cellular Biotechnology and Haematology Department, Umberto I University Hospital, Roma, Italy, Haemophilia Centre, S. Matteo Hospital, Pavia, Italy, Centre of Haemorrhagic and Thrombotic Diseases, University of Palermo, Palermo, Italy, Haemophilia and Thrombosis Centre, S. Giovanni Bosco Hospital, Napoli, Italy, Centre of Coagulation Diseases, Hospital of Macerata, Macerata, Italy, Haematology and Transfusion Medicine Department, Luigi Sacco Hospital, Milano, Italy, Center of Coagulation Diseases, SS Annunziata Hospital, Sassari, Italy, Haematology Department, VE Ferrarotto and S. Bambino University Hospital, Catania, Italy, Transfusion Medicine and Immune-haematology Department, Giovanni XXIII Hospital, Bergamo, Italy, Medicine Department, Humanitas Clinical Institute, Rozzano (Milano), Italy and Centre of Haemorrhagic and Thrombotic Diseases, Pugliese-Ciaccio Hospital, Catanzaro, Italy. E-mail: zanezio61@gmail.com